About a year and a half ago, AIFA published a call for studies on therapeutic sequences in neoplasms. ASL Napoli 1 Centro participated with Dr. Bruno Daniele for the "hepatocellular carcinoma" neoplasm, with the aim of understanding the optimal sequence of drugs used in these pathologies.
"We submitted a project (approximately 40 Italian oncology and hepatology centers) and yesterday the ranking was published, with the ASL Napoli 1 Centro project winning/funded for approximately 2,5 million euros."
"We are proud of this result and will implement every appropriate measure to achieve the objectives set for this important field research." AIFA has published the rankings of the calls for proposals for trials in non-small cell lung cancer, renal cell carcinoma, and hepatocellular carcinoma," commented the ASL Napoli 1 Centro.
"We express our satisfaction with the awarding of the three AIFA calls for independent research.
It might interest you
Furthermore, there are serious critical issues in the availability of personnel and a solid digital infrastructure. Today, in Italy, only 15% of studies are non-profit. These elements require a change of pace and the commitment of the Italian Medicines Agency is going in the right direction. The 3 calls, in fact, concern therapeutic sequence studies, which can optimize the effectiveness of the therapeutic options available throughout the patient's entire treatment pathway".
This is the comment of Francesco Perrone, President of AIOM (Italian Association of Medical Oncology), on the publication of the winners of the 3 AIFA calls for independent research in non-small cell lung cancer (Department of Oncology, University of Turin), renal cell carcinoma (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan) and hepatocellular carcinoma (ASL Napoli 1 Centro, Naples).
The total funding foreseen is equal to 7 million and 500 thousand euros (two million and five hundred thousand euros for each call). In one year (2021-2022), in our country, clinical studies not sponsored by the pharmaceutical industry have gone from 22,6% to 15% of the total.
"A decrease of over 7% in just 12 months, a sign of an impoverishment of the non-profit research system in Italy. This, for oncology, represents a very significant problem - underlines Evaristo Maiello, President of the Federation of Italian Cooperative Oncology Groups (FICOG) -. It is very important that other AIFA calls for independent research are also promoted which, if supported, can achieve the triple mission of improving clinical practice, increasing the level of knowledge on new drugs and acting as support for reimbursement policies".
Leave a comment